Vir Biotechnology Announces Appointment of Suzanne Topalian to its Board of Directors

SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR), today announced the appointment of Suzanne Topalian, M.D., to its Board of Directors, effective October 27, 2026. Dr. Topalian is the Bloomberg-Kimmel Professor of Cancer Immunotherapy at the Johns Hopkins University School of Medicine* and serves as Associate Director of the Bloomberg-Kimmel Institute for Cancer Immunotherapy and Director Melanoma/Skin Cancer Program in the Kimmel Cancer Center at Johns Hopkins. “Su.

Business Wire • Oct 28, 2026

Vir Biotechnology: A Big Pharma Collaboration And 2 Clinical Catalysts This Quarter

VIR's PRO-XTEN platform has attracted major pharma collaborations, validating its dual-masked T-cell engager technology for oncology and solid tumors. Near-term catalysts include ECLIPSE program readouts for hepatitis delta (Q4'26/Q1'27) and VIR-5818 oncology data, with positive outcomes likely based on prior results. VIR's competitors in hepatitis delta include GILD and MIRM, but VIR's prior data suggests exceptional efficacy in hepatitis delta, which may differentiate its therapeutic.

Seeking Alpha • Oct 27, 2026

Vir Biotechnology to Host Conference Call for Third Quarter 2026 Financial Results

SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR), today announced that it will host a conference call at 4:30 p.m. ET / 1:30 p.m. PT on Wednesday, November 4 to provide a corporate update and discuss its financial results for the third quarter ended September 30, 2026. The conference call may be accessed on the Events & Presentations page of the Vir Biotechnology website. About Vir Biotechnology Vir Biotechnology, Inc. is a clinical-stage biopharmaceutical company focus.

Business Wire • Oct 21, 2026

Vir Biotechnology Enters Multi-Program Collaboration and License Agreement with Gilead Sciences to Discover and Develop Novel PRO-XTEN® Dual-masked T-cell Engagers for Solid Tumors

SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR), today announced a collaboration and license agreement with Gilead to discover and engineer three novel PRO-XTEN® dual-masked T-cell engager (TCE) development candidates targeting selected solid tumor-associated antigens. Gilead will have an exclusive license to develop and commercialize the novel TCEs. Through this collaboration, Vir Biotechnology will apply its deep expertise in TCE discovery and protein engineering, its pr.

Business Wire • Oct 14, 2026

Vir Biotechnology, Gilead Strike Deal for Novel Tumor Treatments

Vir Biotechnology Inc. (NASDAQ:VIR) announced a major collaboration with Gilead Sciences Inc. (NASDAQ:GILD) to create three novel T-cell engagers (TCEs) aimed at treating solid tumors.

Benzinga • Oct 14, 2026

Vir Biotechnology Announces PSMA-targeted PRO-XTEN® Dual-masked T-cell Engager VIR-5500 Received FDA Fast Track Designation for the Treatment of Prostate Cancer

SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that the U.S. Food and Drug Administration (FDA) granted Fast Track designation to VIR-5500, a PSMA-targeted PRO-XTEN® dual-masked T-cell engager (TCE), for the treatment of late-line metastatic castration-resistant prostate cancer (mCRPC). VIR-5500 is being co-developed by Astellas Pharma Inc. and Vir Biotechnology through a global strategic collaboration. “Receiving Fast Track designation reflects the potent.

Business Wire • Oct 8, 2026

Vir Biotechnology Appoints David Liu as Chief Medical Officer

SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the appointment of David Liu, M.D., Ph.D., as Executive Vice President and Chief Medical Officer (CMO), effective October 12, 2026. Dr. Liu will be responsible for leading the clinical development, medical affairs and regulatory affairs functions. “David brings extensive immuno-oncology leadership experience, a strong track record of advancing and securing approvals for innovative cancer therapies and deep expe.

Business Wire • Oct 7, 2026

Vir Biotechnology to Present Expanded Phase 2 SOLSTICE Results for Elebsiran and Tobevibart in Hepatitis Delta at AASLD's The Liver Meeting® 2026

SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the Company will present data from the Phase 2 SOLSTICE trial evaluating the combination of elebsiran and tobevibart for chronic hepatitis delta at the upcoming American Association for the Study of Liver Diseases (AASLD) The Liver Meeting® 2026 in Denver, CO, November 5-9, 2026. Efficacy of elebsiran (VIR-2218) and tobevibart (VIR-3434) in participants with chronic hepatitis delta infection: Patterns of HDV R.

Business Wire • Oct 5, 2026

Vir Biotechnology Appoints Aziz Sawaf as Chief Financial Officer

SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology Appoints Aziz Sawaf as Chief Financial Officer.

Business Wire • Oct 1, 2026

Vir Biotechnology: Astellas Deal Highlights The Platform's Value

Vir Biotechnology is now a two-engine company, with major pharma partnerships and a fully enrolled hepatitis delta phase 3 program. Gilead's bulevirtide launch is expanding hepatitis delta diagnosis, indirectly benefiting VIR's upcoming ECLIPSE trials targeting bulevirtide non-responders. The Astellas deal validates VIR's PRO-XTEN platform, providing $335 million in upfront and near-term payments and a premium equity investment.

Seeking Alpha • Sep 29, 2026